Last reviewed · How we verify
NCT04731935
Novel Earpiece for Transcutaneous Auricular Neurostimulation (tAN) for Symptoms of Opioid Withdrawal
NA trial testing Sparrow Therapy System in Opioid-use Disorder in 6 participants. Completed in 26 May 2021.
26 May 2021
Quick facts
| Lead sponsor | Spark Biomedical, Inc. |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 6 |
| Start date | 18 March 2021 |
| Primary completion | 26 May 2021 |
| Estimated completion | 26 May 2021 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Sparrow Therapy System
Conditions studied
- Opioid-use Disorder — all drugs for Opioid-use Disorder →
- Opioid Withdrawal — all drugs for Opioid Withdrawal →
Sponsor
Spark Biomedical, Inc.
Who can join
Adults 18 to 65, any sex, with Opioid-use Disorder or Opioid Withdrawal. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The objective of this study is to evaluate whether tAN via the tragus (vagal) and auriculotemporal (trigeminal) nerve pathways results in a clinically meaningful reduction in opioid withdrawal symptoms.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Neuromodulation Strategies to Reduce Inflammation and Improve Lung Complications in COVID-19 Patients.
Czura CJ, Bikson M, Charvet L, Chen JDZ, et al · · 2022 · cited 13× · PMID 35911909 · DOI 10.3389/fneur.2022.897124
Verify or expand the search:
- PubMed search for NCT04731935
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Opioid-use Disorder
Currently open trials in the same condition.
- NCT04783558 — Effective Caregiving for Neonatal Abstinence Syndrome: Testing an Instructional Mobile Technology Platform for High-Risk · NA · active not recruiting
- NCT05011266 — Efficacy of Buprenorphine and XR-Naltrexone Combination for Relapse Prevention in Opioid Use Disorder · Phase 2, PHASE3 · recruiting
- NCT05039554 — Randomized Trial of ACT and a Care Management App in Primary Care-based Buprenorphine Treatment · NA · recruiting
- NCT05033028 — Smartphones for Opiate Addiction Recovery · Phase 3 · recruiting
- NCT04738825 — Promoting HIV Risk Reduction Among People Who Inject Drugs: A Stepped Care Approach Using Contingency Management With Pr · NA · recruiting
Other Spark Biomedical, Inc. trials
Trials by the same sponsor.
- NCT07326722 — Delivering tAN to Reduce HMB: The LUNA Study · NA · recruiting
- NCT07281261 — tAN for Substance Use Disorder · NA · recruiting
- NCT07109349 — tAN for First Responders · NA · recruiting
- NCT06487533 — Sensing Physiological Symptoms of Opioid Withdrawal and Cravings in Patients With Opioid Use Disorder · recruiting
- NCT06814028 — Transcutaneous Auricular Neurostimulation as a Treatment for Women With Heavy Menstrual Bleeding: A Dose-finding Trial · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04731935 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Spark Biomedical, Inc.
- Last refreshed: 19 August 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04731935.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing